Applied Therapeutics, Inc. (NASDAQ:APLT) Receives Consensus Rating of “Moderate Buy” from Analysts

Applied Therapeutics, Inc. (NASDAQ:APLT) has received a consensus recommendation of “Moderate Buy” from the six research firms that are presently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $6.10.

APLT has been the topic of several research analyst reports. Royal Bank of Canada reduced their price objective on shares of Applied Therapeutics from $4.00 to $1.50 and set a “sector perform” rating on the stock in a report on Friday, December 20th. UBS Group reiterated a “neutral” rating and set a $2.00 price target (down from $13.00) on shares of Applied Therapeutics in a research note on Monday, December 2nd. William Blair lowered shares of Applied Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, December 23rd. Citigroup cut their price target on shares of Applied Therapeutics from $13.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 29th. Finally, Robert W. Baird cut their price target on shares of Applied Therapeutics from $14.00 to $5.00 and set an “outperform” rating on the stock in a research note on Friday, November 29th.

Institutional Trading of Applied Therapeutics

Large investors have recently made changes to their positions in the company. Y Intercept Hong Kong Ltd purchased a new stake in shares of Applied Therapeutics during the third quarter worth approximately $149,000. Intech Investment Management LLC purchased a new stake in shares of Applied Therapeutics during the third quarter worth approximately $162,000. Ground Swell Capital LLC purchased a new stake in shares of Applied Therapeutics during the fourth quarter worth approximately $27,000. Toronto Dominion Bank purchased a new stake in shares of Applied Therapeutics during the fourth quarter worth approximately $27,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Applied Therapeutics during the second quarter worth approximately $172,000. 98.31% of the stock is currently owned by hedge funds and other institutional investors.

Applied Therapeutics Trading Down 6.2 %

Shares of APLT opened at $0.53 on Friday. The firm has a market cap of $61.67 million, a P/E ratio of -0.33 and a beta of 1.88. Applied Therapeutics has a 12-month low of $0.53 and a 12-month high of $10.62. The company’s 50-day moving average price is $0.72 and its 200 day moving average price is $4.78.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.